Results 171 to 180 of about 19,955 (310)
The expression, regulation, and function of human endogenous retroviruses in genitourinary cancers. [PDF]
Ma W +14 more
europepmc +1 more source
Non‐invasive papillary urothelial carcinomas with minor high‐grade component are not associated with a more indolent behavior and should likely be regarded as high‐grade carcinomas. Aims The latest WHO edition proposed using a cut‐off of ≥5% high‐grade component (%HGc) as a criterion to label non‐invasive papillary urothelial carcinomas as high‐grade ...
Mina S. Farag +5 more
wiley +1 more source
Life after radical cystectomy: A mixed-methods targeted review of patient-reported quality of life following bladder removal. [PDF]
Griebsch I +7 more
europepmc +1 more source
Abstract Background There is evidence in the civilian population that resuscitation using group O low titer whole blood (WB) may provide survival benefits to traumatically injured patients. However, there is limited information in the literature concerning the use of WB in non‐trauma patients requiring resuscitation.
Emmanuel A. Fadeyi +6 more
wiley +1 more source
Initial results with an absorbable urologic scaffold to mitigate early urinary incontinence following radical prostatectomy: the ARID study. [PDF]
Gahan JC +4 more
europepmc +1 more source
Patient blood management and surgery: Impact of new surgical techniques on transfusion needs
Abstract Background and Objectives Patient blood management (PBM) is a multidisciplinary approach aimed at reducing the use of blood products. It considers the patient's own blood as a valuable resource to preserve and seeks to avoid the routine use of transfusions to treat anaemia.
Francois Ansart, France Pirenne
wiley +1 more source
Systematic druggable genome-wide analysis to identify potential therapeutic targets for urologic diseases. [PDF]
Shi Y, Chen H, Zhang X, Yin C, Lian P.
europepmc +1 more source
Lower extremity lymphedema after pelvic nodal dissection for urologic cancers is associated with metastatic recurrence. [PDF]
Pogson K +6 more
europepmc +1 more source
What's new? The combination of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma has demonstrated durable response and tolerability in clinical trials. However, inclusion criteria for clinical studies are restrictive, and patients in the real‐world setting tend to have more comorbidities.
Hendrik Dinkel +21 more
wiley +1 more source

